ElenaShagisultanovaMD

Oncology • Aurora, CO

Physician

Join to view full profile

Dr. Shagisultanova is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Shagisultanova's full profile

Already have an account?

Office
1665 Aurora CT
Mail Stop F704 Anschutz Cancer Pavilion Acp CP 5328
Aurora, CO 80045
Phone+1 858-722-9600

Education & Training

Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
St Mary's Hospital and Medical CenterResidency, Internal Medicine, 2009 - 2012
Bashkir State Med UnivClass of 1997

Certifications & Licensure

CA State Medical License 2011 - 2025
CO State Medical License 2015 - 2025
PA State Medical License 2012 - 2016
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer Start of enrollment: 2017 Nov 27
Completed
Phase 1, Phase 2

Publications & Presentations

PubMed

8 citations
Overall survival is the lowest among young women with postpartum breast cancer.
Elena Shagisultanova, Dexiang Gao, Eryn Callihan, Hannah J Parris, Betsy Risendal
European Journal of Cancer. 2022-06-01
37 citations
EGFR and RB1 as Dual Biomarkers in HPV-Negative Head and Neck Cancer
Tim N. Beck, Rachel Georgopoulos, Elena Shagisultanova, David Sarcu, Elizabeth Handorf
Molecular Cancer Therapeutics. 2016-10-01
24 citations
Mutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Aryana R Rasti, Amy Guimaraes-Young, Farrah Datko, Virginia F Borges, Dara L Aisner
JCO Precision Oncology. 2022-03-01

Lectures

Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Tucatinib (ONT-380) Progressing in Pivotal Trial Against HER2+ Breast CancerJanuary 10th, 2017
Tablets Show Promise as an Alternative to Chemotherapy in CU Cancer Center Member’s Breast Cancer StudyFebruary 1st, 2024